MBZUAI – Building Humanity’s Symbiotic Relationship With AI

MBZUAI, UAE’s AI-only university, builds talent and open models for underserved languages, linking research, industry and ...

Tiny galaxy, big find: Black hole discovered in nearby Segue 1

Small and unassuming, Segue 1 is a nearby dwarf galaxy containing only a handful of stars—too few to provide the gravity ...

California wants to overhaul high school learning. This school is leading the way

This California high school features multi-hour labs that blend topics and the curriculum is tailored to students’ interests.

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid ...

How Companies Are Entering Data's Next Act: From Asset To Revenue

Nacho De Marco is the CEO of BairesDev, an award-winning nearshore software outsourcing company, and the cofounder of VC firm BDev Ventures.

Seattle students use free tuition to fuel their futures

Seven years in, the Seattle Promise Program, which offers free tuition to Seattle Colleges for SPS graduates, has increased ...
Khaleej Times on MSN

Dubai’s visionary drive: Building infrastructure for global impact

Empowered by visionary leadership, we built integrated infrastructure that strengthened Dubai’s global competitiveness; The ...
TMCnet

AI's Growth Has a Power Problem -- Natural Hydrogen Could Be the Perfect Solution

AI's rapid expansion is redefining global energy demand, forcing a rethink of how the world generates and delivers power. MAX ...
The Malaysian Reserve

Onward Therapeutics Exercises Exclusive Option and Signs Worldwide License Agreement with Institut du Cancer de Montpellier for Novel Onco-Metabolism Program

This license agreement builds upon the exclusive collaboration and option agreement signed between Onward Therapeutics France and ICM, Inserm and Université de Montpellier in June 2021, under which ...

Kymera Therapeutics, Inc.: Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual ...

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to appro ...